{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:49:27Z","timestamp":1761540567789},"reference-count":36,"publisher":"Wiley","issue":"s4","license":[{"start":{"date-parts":[[2004,10,8]],"date-time":"2004-10-08T00:00:00Z","timestamp":1097193600000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2004,10]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold> Haemophilia replacement factors, both plasma\u2010derived and recombinant, are in relatively short supply and are high\u2010cost products. This has stymied the study and development of alternative methods of administration of haemophilia therapy even in the most economically advanced countries, owing to the large amounts of material needed because bioabsorption and bioavailability of haemophilic factors can be less than 10% when using non\u2010intravenous routes of delivery. There is therefore a need to increase access to therapy worldwide by decreasing the cost and increasing the abundance so that therapy can be achieved through simplified, alternative delivery methods. Transgenic livestock have been used to produce haemophilic factors in milk. Only the pig mammary gland has been shown to carry out the post\u2010translational processing necessary to enable both the biological activity and long circulation half\u2010life needed for therapeutic glycoproteins. Furthermore, the large amounts of recombinant protein that can be produced from pig milk make feasible the use of alternative delivery methods such as oral, intratracheal, subcutaneous, and intramuscular administration.<\/jats:p>","DOI":"10.1111\/j.1365-2516.2004.00983.x","type":"journal-article","created":{"date-parts":[[2004,10,8]],"date-time":"2004-10-08T16:04:19Z","timestamp":1097251459000},"page":"70-76","source":"Crossref","is-referenced-by-count":16,"title":["Haemophilic factors produced by transgenic livestock: abundance that can enable alternative therapies worldwide"],"prefix":"10.1111","volume":"10","author":[{"given":"K. E.","family":"Van Cott","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. E.","family":"Monahan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. C.","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. H.","family":"Velander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,10,8]]},"reference":[{"key":"e_1_2_9_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1355-0691.2004.00881.x"},{"key":"e_1_2_9_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2002.00695.x"},{"key":"e_1_2_9_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1538-7836.2003.00262.x"},{"key":"e_1_2_9_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2003.00343.x"},{"key":"e_1_2_9_6_2","volume-title":"Drug Topics Red Book.","year":"2003"},{"key":"e_1_2_9_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1250"},{"key":"e_1_2_9_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.2000.00633.x"},{"key":"e_1_2_9_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00757.x"},{"key":"e_1_2_9_10_2","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.7.5.8462786"},{"key":"e_1_2_9_11_2","doi-asserted-by":"crossref","first-page":"9622","DOI":"10.1016\/S0021-9258(18)67559-3","article-title":"Expression, purification, and characterization of recombinant gamma\u2010carboxylated factor IX synthesized in Chinese hamster ovary cells","volume":"261","author":"Kaufman RJ","year":"1986","journal-title":"J Biol Chem"},{"issue":"2","key":"e_1_2_9_12_2","first-page":"4","article-title":"The manufacturing process for recombinant factor IX","volume":"35","author":"Harrison S","year":"1998","journal-title":"Semin Hematol"},{"issue":"2","key":"e_1_2_9_13_2","first-page":"11","article-title":"Biochemical characterization of recombinant factor IX","volume":"35","author":"Bond M","year":"1998","journal-title":"Semin Hematol"},{"key":"e_1_2_9_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2002.00039.x"},{"key":"e_1_2_9_15_2","volume-title":"Essentials of Glycobiology","author":"Varki A","year":"1999"},{"key":"e_1_2_9_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.jbchem.a022738"},{"key":"e_1_2_9_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3591"},{"key":"e_1_2_9_18_2","first-page":"705","article-title":"Asparagine\u2010linked glycosylation sites within the B domain of coagulation Factor VIII improve secretion efficiency","volume":"98","author":"Tendulkar R","year":"2001","journal-title":"Blood"},{"key":"e_1_2_9_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/81098"},{"key":"e_1_2_9_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/85559"},{"key":"e_1_2_9_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.9.s1.12.x"},{"key":"e_1_2_9_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0887-7963(96)80089-7"},{"key":"e_1_2_9_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2003.11.006"},{"key":"e_1_2_9_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1097-971"},{"key":"e_1_2_9_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0589-487"},{"key":"e_1_2_9_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4615-2548-6_3"},{"key":"e_1_2_9_27_2","doi-asserted-by":"crossref","first-page":"4561","DOI":"10.1182\/blood.V91.12.4561","article-title":"Transgenically produced human antithrombin: structural and functional comparison to human plasma\u2010derived antithrombin","volume":"91","author":"Edmunds T","year":"1998","journal-title":"Blood"},{"key":"e_1_2_9_28_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2001-16893"},{"key":"e_1_2_9_29_2","first-page":"265","article-title":"Minimization of viral contamination in human pharmaceuticals produced in the milk of transgenic goats","volume":"88","author":"Ziomek CA","year":"1996","journal-title":"Dev Biol Stand"},{"key":"e_1_2_9_30_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2002.00698.x"},{"key":"e_1_2_9_31_2","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.18788-0"},{"key":"e_1_2_9_32_2","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1055\/s-0037-1615602","article-title":"Intratracheal administration of recombinant human factor IX (BeneFix) achieves therapeutic levels in hemophilia B dogs","volume":"85","author":"Russell KE","year":"2001","journal-title":"Thromb Haemost"},{"key":"e_1_2_9_33_2","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1055\/s-0038-1656082","article-title":"Extravascular administration of factor IX: potential for replacement therapy of canine and human hemophilia B","volume":"77","author":"Liles D","year":"1997","journal-title":"Thromb Haemost"},{"key":"e_1_2_9_34_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613091"},{"key":"e_1_2_9_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(80)90495-X"},{"key":"e_1_2_9_36_2","unstructured":"HorikoshiI SakuragawaN UenoM TakahashiK.Pharmaceutical Composition for Oral Administration Containing Coagulation Factor VIII or IX.US Patent 4183960 1982."},{"key":"e_1_2_9_37_2","unstructured":"National Hemophilia Foundation.Research and development of improved coagulation products that would expedite the transition to total prophylaxis for all persons with coagulation disorders are strongly encouraged. Available at:http:\/\/www.hemophilia.org\/research\/masac\/masac151.htm"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2004.00983.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2516.2004.00983.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T13:07:22Z","timestamp":1695820042000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2004.00983.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10]]},"references-count":36,"journal-issue":{"issue":"s4","published-print":{"date-parts":[[2004,10]]}},"alternative-id":["10.1111\/j.1365-2516.2004.00983.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2004.00983.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,10]]}}}